Chikungunya test vaccine shows promise: makers基孔肯雅熱疫苗試驗表明承諾:製造商

AFP
August 16, 2014, 12:02 am TWN

PARIS -- A candidate vaccine against the joint disease chikungunya, endemic to Africa and south Asia but moving north- and westward, showed promise by provoking an immune response in human trials, its developers said Friday.

The trial drug is made with nanoparticles that resemble a West African strain of the virus, which causes high fever and intensely painful arthritis, said a study in The Lancet medical journal.

These virus-like particles (VLPs) are meant to mimic the immune-stimulating effects of the actual virus particles, but cannot cause disease as they contain no viral DNA.

In tests on rhesus macaques, the vaccine provided protection from infection and its first human tests have now also yielded positive results.

“All injections were well tolerated, with no serious adverse events reported,” wrote the authors of the study.

Antibodies are protective proteins produced by the immune system in response to foreign agents like viruses.

“Eleven months after vaccination, antibody levels were comparable to those seen in people who had recovered after natural chikungunya infection, suggesting that the ... vaccine could provide long-term protection against the virus,” said study co-author Julie Ledgerwood of the U.S.-based National Institutes of Health.

Europe reported its first locally transmitted case of the mosquito-borne illness in 2007, in Italy.

The disease was first noted in the Western Hemisphere in December, and the United States had its first home-grown case last month.

There is no vaccine to prevent the disease and no medicine to treat it but a number of vaccines are at different stages of testing.

Ledgerwood said a VLP vaccine should be “relatively economical” to produce in large quantities.

But Ann Powers from the U.S.-based Centers for Disease Control and Prevention wrote in a comment: “The market might not be large enough to justify the investment.”

The cost of developing a vaccine, from preclinical studies to registration, was about US$200-US$500 million, she said.


基孔肯雅熱疫苗試驗表明承諾:製造商

法新社
2014年8月16日,上午12時02分TWN

巴黎 - 對關節病基孔肯雅熱,特有的非洲和南亞,但移動的北部和西候選疫苗,顯露才華挑起的人體試驗的免疫反應,它的開發者說,星期五。

該試驗的藥物製成納米粒子類似的病毒,導致高熱和劇烈疼痛性關節炎的西非緊張,說在柳葉刀醫學雜誌上的一項研究。

這些病毒樣顆粒(VLP)是指以模擬實際的病毒顆粒的免疫刺激效果,但不能導致疾病,因為它們不含有病​​毒DNA。

在恒河猴實驗,感染的疫苗提供保護和它的第一個人體試驗現在也取得了積極的成果。

“所有注射的耐受性良好,沒有嚴重不良事件報告,寫道:”該研究的作者。

抗體是由免疫系統響應於外部代理類病毒產生的保護性蛋白質。

“接種疫苗十一個月後,抗體水平相若看到的人誰曾自然感染基孔肯亞病後痊癒,這表明...疫苗能對抗病毒提供了長期保護”之稱的研究的共同作者朱莉萊傑伍德美國的國立衛生研究院。

歐洲報導的蚊子傳播的疾病的第一本地傳輸的情況下,2007年,在意大利。

本病最早是在西半球指出,在12月合約,美國有它的第一個土生土長的情況下最後一個月。

目前尚無疫苗預防本病無藥治療,但一些疫苗是在測試的不同階段。

萊傑伍德說的VLP疫苗應該是“相對經濟”,以大量生產。

但安國從美國的疾病控制中心和預防中寫道評論:“市場可能沒有大到足以證明投資。”

研製疫苗的成本,從臨床前研究到註冊,大約是200美元,500美元萬美元,她說。

    全站熱搜

    evita6804 發表在 痞客邦 留言(0) 人氣()